Treatment of Dravet Syndrome With Fenfluramine (Expanded Access Protocol)
Overview
The purpose of this research study is to (1) provide access to fenfluramine for patients with intractable epilepsy associated with Dravet syndrome, and (2) evaluate the safety of fenfluramine.
Study Type
- Study Type: Expanded Access
Detailed Description
The purpose of this research study is to (1) provide access to fenfluramine for patients with intractable epilepsy associated with Dravet syndrome, and (2) evaluate the safety of fenfluramine.
Interventions
- Drug: Fenfluramine
- The treatment plan for this Expanded Access Protocol is for patients with Dravet syndrome who do not qualify for participation in one of the ongoing ZX008 (fenfluramine hydrochloride) clinical trials.
Participating in This Clinical Trial
Inclusion Criteria
- Genetic diagnosis of Dravet syndrome with intractable seizures despite failing all available medications for seizures.
Gender Eligibility: All
Minimum Age: 2 Years
Maximum Age: N/A
Investigator Details
- Lead Sponsor
- University of California, Los Angeles
- Provider of Information About this Clinical Study
- Principal Investigator: Shaun Hussain, MD, Associate Professor – University of California, Los Angeles
- Overall Contact(s)
- Angela Martinez, 310-206-4037, angelamartinez@mednet.ucla.edu
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.